Clearside Biomedical, Inc. (CLSD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clearside Biomedical, Inc. (CLSD) trades at $0.41 with AI Score 51/100 (Grade B). Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing therapies for the back of the eye through its suprachoroidal space delivery platform. Market cap: $2.15M, Sector: Healthcare.
Price live · AI analysis from May 31, 2026CLSD stock analysis for 2026: Analysts have set a consensus price target of $60.00 for Clearside Biomedical, Inc., suggesting 14534.1% upside from the current price of $0.41. The AI MoonshotScore is 51/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
CLSD: 4/7 perspectives are bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Clearside Biomedical, Inc. (CLSD) Healthcare & Pipeline Overview
Clearside Biomedical, Inc. specializes in innovative drug delivery to the back of the eye, primarily through its suprachoroidal space injection platform. With XIPERE approved for uveitic macular edema and a pipeline targeting diabetic macular edema and macular degeneration, Clearside is carving a niche in the competitive biotechnology sector.
What Is the Investment Thesis for CLSD?
Clearside Biomedical presents a focused investment opportunity within the ophthalmology space, driven by its innovative suprachoroidal space (SCS) drug delivery platform. The company's approved product, XIPERE, for uveitic macular edema, provides a revenue stream and validates the SCS approach. Key value drivers include the successful clinical development and commercialization of CLS-AX and CLS-301, targeting larger market opportunities like diabetic macular edema and macular degeneration. The company's collaborations with Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences also represent potential revenue streams and platform validation. However, the company's negative profit margin of -780.9% and reliance on clinical trial outcomes pose significant risks. Upcoming clinical trial results for CLS-AX and CLS-301 will be critical catalysts, while potential delays or failures in these trials represent key risks.
Based on FMP financials and quantitative analysis
CLSD Key Highlights
- XIPERE is approved for the treatment of uveitic macular edema, providing an established revenue stream.
- Gross margin of 85.6% indicates strong pricing power for XIPERE.
- CLS-AX is in Phase 1/2a clinical trial, targeting retinal diseases.
- CLS-301 is being developed for diabetic macular edema and macular degeneration, large market opportunities.
- Collaborations with Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences validate the SCS delivery platform.
Who Are CLSD's Competitors?
CLSD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $528.88 | +0.16% | $134.23B | 99 |
| ALNY Alnylam Pharmaceuticals, Inc. | $313.04 | +0.08% | $41.79B | 95 |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLSD's Key Strengths?
- Innovative suprachoroidal space (SCS) drug delivery platform.
- Approved product (XIPERE) for uveitic macular edema.
- Strong gross margin on XIPERE sales.
- Experienced management team.
What Are CLSD's Weaknesses?
- Negative profit margin.
- Reliance on clinical trial outcomes.
- Limited product portfolio.
- Small employee base.
What Could Drive CLSD Stock Higher?
- Clinical trial results for CLS-AX (axitinib injectable suspension) in Phase 1/2a clinical trial for retinal diseases.
- Clinical trial results for CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration.
- Expansion of XIPERE label to include other indications beyond uveitic macular edema.
- Strategic partnerships with pharmaceutical companies to expand the reach of Clearside's technology.
What Are the Key Risks for CLSD?
- Financial-distress signal — its Altman Z-Score of -48.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for CLS-AX and CLS-301.
- Competition from established pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining approvals for new therapies.
- Dependence on the commercial success of XIPERE.
- Negative profit margin and need for additional financing.
What Are the Growth Opportunities for CLSD?
- Expansion of XIPERE Label: Clearside has the opportunity to expand the label for XIPERE to include other indications beyond uveitic macular edema. This would involve conducting additional clinical trials to demonstrate efficacy and safety in new patient populations. The market for macular edema associated with other conditions, such as retinal vein occlusion, represents a significant growth opportunity, potentially increasing XIPERE's market reach and revenue.
- Advancement of CLS-AX: CLS-AX, an axitinib injectable suspension, is currently in Phase 1/2a clinical trial for retinal diseases. Positive results from this trial could pave the way for further clinical development and eventual commercialization. Axitinib is a VEGF inhibitor, a proven mechanism for treating retinal diseases. Successful development of CLS-AX could provide Clearside with a second commercial product targeting a broader range of retinal conditions.
- Development of CLS-301: CLS-301, an integrin inhibitor suspension, is being developed for the treatment of diabetic macular edema and macular degeneration. These are large and growing markets with significant unmet needs. Successful development of CLS-301 could position Clearside as a major player in the treatment of these diseases. The integrin inhibition mechanism offers a novel approach to addressing the underlying pathology of these conditions.
- Strategic Partnerships: Clearside has established collaborations with companies like Bausch Health, Arctic Vision, REGENXBIO, and Aura Biosciences. These partnerships provide opportunities for revenue generation, platform validation, and expansion into new markets. Further strategic partnerships with other pharmaceutical and biotechnology companies could accelerate the development and commercialization of Clearside's SCS delivery platform and pipeline products.
- Geographic Expansion: Clearside has the opportunity to expand its geographic reach beyond the United States. Partnering with companies that have established distribution networks in other regions, such as Europe and Asia, could accelerate the commercialization of XIPERE and other pipeline products. The global market for ophthalmic therapies is substantial, and geographic expansion represents a significant growth opportunity for Clearside.
What Opportunities Does CLSD Have?
- Expansion of XIPERE label to other indications.
- Successful development and commercialization of CLS-AX and CLS-301.
- Strategic partnerships with pharmaceutical companies.
- Geographic expansion into new markets.
What Threats Does CLSD Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Patent challenges.
What Are CLSD's Competitive Advantages?
- Proprietary suprachoroidal space (SCS) injection platform.
- Approved product (XIPERE) for uveitic macular edema.
- Pipeline of SCS-delivered therapies targeting large markets.
- Established collaborations with pharmaceutical companies.
What Does CLSD Do?
Clearside Biomedical, Inc., founded in 2011 and headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing and delivering therapies to the back of the eye. The company's core technology revolves around accessing the suprachoroidal space (SCS), a space located between the sclera and the choroid, to deliver drugs directly to the retina and other posterior structures of the eye. This targeted approach aims to improve drug efficacy and reduce systemic side effects compared to traditional methods. Clearside's lead product, XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), is approved for the treatment of uveitic macular edema. Beyond XIPERE, Clearside is advancing a pipeline of SCS-delivered therapies, including CLS-AX (axitinib injectable suspension) in Phase 1/2a clinical trial for retinal diseases and CLS-301, an integrin inhibitor suspension for diabetic macular edema and macular degeneration. Clearside has established collaborations with companies like Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences to expand the reach and application of its SCS delivery platform.
What Products and Services Does CLSD Offer?
- Develops therapies for the back of the eye.
- Utilizes a suprachoroidal space (SCS) injection platform for targeted drug delivery.
- Offers XIPERE for the treatment of uveitic macular edema.
- Develops CLS-AX for retinal diseases.
- Develops CLS-301 for diabetic macular edema and macular degeneration.
- Collaborates with pharmaceutical companies to expand the reach of its technology.
How Does CLSD Make Money?
- Develops and commercializes ophthalmic therapies.
- Generates revenue from sales of XIPERE.
- Out-licenses its SCS delivery platform to other companies.
- Receives milestone payments and royalties from collaborations.
What Industry Does CLSD Operate In?
Clearside Biomedical operates in the competitive biotechnology industry, specifically within the ophthalmology segment. The market for treatments targeting retinal diseases, such as diabetic macular edema and macular degeneration, is substantial and growing, driven by an aging population and increasing prevalence of diabetes. Clearside's suprachoroidal space (SCS) delivery platform offers a differentiated approach compared to traditional intravitreal injections, potentially improving drug efficacy and reducing side effects. The company competes with established pharmaceutical companies and other biotechnology firms developing novel therapies for eye diseases. Success in this market depends on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Who Are CLSD's Key Customers?
- Patients with uveitic macular edema.
- Ophthalmologists and retinal specialists.
- Hospitals and clinics.
- Pharmaceutical companies through collaborations.
Company Profile
Clearside Biomedical, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alpharetta, US. The company is led by CEO George Lasezkay. CLSD has traded publicly since 2016.
Clearside Biomedical, Inc. Financial Trajectory
Clearside Biomedical, Inc. (CLSD) reported $201K in revenue for Q3 2025, a decline of 59.1% compared to the prior quarter. The company recorded a net loss of $6.0M, with diluted EPS of $-1.14. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CLSD averaged $-1.28 in diluted EPS.
How Clearside Biomedical, Inc. Is Valued
Clearside Biomedical, Inc. carries a market capitalization of $2.15M, placing it in the micro-cap category. Relative to its peer group, CLSD's quantitative score of 51/100 is below the peer average of 84/100.
ROE 55%Key Financial Metrics
Return on equity for Clearside Biomedical, Inc. stands at 55.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.98 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
Clearside Biomedical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.27 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Clearside Biomedical, Inc. revenue of about $6.8M for fiscal 2026, with EPS near $-3.30. The estimate reflects 4 contributing analysts.
Net buyingInsider Activity
The most recent 2 insider filings for Clearside Biomedical, Inc. break down as 0 sales and 2 purchases. On net that is roughly 350K shares acquired (about $572K) — insiders putting money in tends to read as conviction.
CLSD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential.
- Community sentiment has turned optimistic as discussions around new product developments have gained traction.
- Positive news regarding clinical trial advancements has sparked interest, positioning the company favorably in the eyes of investors.
- The growing focus on eye disease treatments aligns well with Clearside's offerings, suggesting a robust market opportunity ahead.
Bear Case
- Concerns about funding and cash flow management have been prevalent, raising doubts about the company's financial stability.
- Recent bearish sentiment in social discussions reflects skepticism regarding the company's ability to deliver on its promises.
- Market perception has been dampened by previous delays in product launches, leading to a lack of trust among investors.
- Increased competition in the biotech sector may pose challenges, making it harder for Clearside to differentiate itself and maintain market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $201,000 | -$6M | -$1.14 |
| Q2 2025 | $492,000 | -$4M | -$0.87 |
| Q1 2025 | $2M | -$8M | -$1.65 |
| Q4 2024 | $306,000 | -$7M | -$1.44 |
Based on FMP financials and quantitative analysis
CLSD Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Dec 16, 2019
CLSD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLSD.
Price Targets
Consensus target: $60.00
CLSD MoonshotScore
What does this score mean?
The MoonshotScore rates CLSD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: George Lasezkay
CEO
George Lasezkay serves as the CEO of Clearside Biomedical, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on ophthalmology. Prior to joining Clearside, he held leadership positions at various companies, where he oversaw the development and commercialization of ophthalmic therapies. He brings a wealth of knowledge in drug development, regulatory affairs, and commercial strategy to Clearside Biomedical.
Track Record: Under George Lasezkay's leadership, Clearside Biomedical has achieved significant milestones, including the approval and commercialization of XIPERE. He has also overseen the advancement of the company's pipeline of SCS-delivered therapies, including CLS-AX and CLS-301. His strategic decisions have focused on expanding the reach of Clearside's technology through collaborations and partnerships.
CLSD Healthcare Stock FAQ
What does Clearside Biomedical, Inc. do?
Clearside Biomedical, Inc. is a biopharmaceutical company specializing in the development and delivery of therapies to the back of the eye. Its core technology is the suprachoroidal space (SCS) injection platform, which allows for targeted drug delivery to the retina and other posterior structures. The company's lead product, XIPERE, is approved for the treatment of uveitic macular edema. Clearside is also developing a pipeline of SCS-delivered therapies for other retinal diseases, including diabetic macular edema and macular degeneration. The company aims to improve drug efficacy and reduce systemic side effects compared to traditional injection methods.
What do analysts say about CLSD stock?
Analyst coverage of Clearside Biomedical, Inc. is limited, reflecting its small market capitalization and early-stage development. However, analysts generally view the company's suprachoroidal space (SCS) drug delivery platform as a promising technology with the potential to address unmet needs in the treatment of retinal diseases. Key valuation metrics include the potential peak sales of XIPERE and the pipeline products, as well as the value of the company's collaborations. Growth considerations include the successful clinical development and commercialization of CLS-AX and CLS-301.
What are the main risks for CLSD?
Clearside Biomedical, Inc. faces several risks, including the potential for clinical trial failures, competition from established pharmaceutical companies, regulatory hurdles, and dependence on the commercial success of XIPERE. The development of new therapies for retinal diseases is a complex and lengthy process, and there is no guarantee that Clearside's pipeline products will be approved. The company also faces competition from other companies developing novel therapies for eye diseases. Regulatory delays or unfavorable decisions could also impact the company's ability to commercialize its products. Additionally, Clearside's financial performance is heavily reliant on the sales of XIPERE, and any decline in sales could negatively impact the company's financial results.
What are the key growth opportunities for CLSD in healthcare?
Clearside Biomedical, Inc.'s key growth opportunities lie in expanding the applications of its suprachoroidal space (SCS) delivery platform. This includes developing new therapies for additional ophthalmic indications, such as glaucoma and age-related macular degeneration (AMD). Geographic expansion into international markets, particularly in regions with high prevalence of retinal diseases, also presents a significant growth opportunity. Furthermore, Clearside can leverage its SCS platform to partner with other pharmaceutical companies, enabling them to deliver their own therapies more effectively to the back of the eye. These strategic collaborations can generate revenue through licensing agreements and milestone payments, driving further growth for the company.
How does Clearside Biomedical, Inc. navigate regulatory approval processes?
Clearside Biomedical, Inc. navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its therapies. The company works closely with regulatory agencies, such as the FDA in the United States, to ensure compliance with all applicable regulations and guidelines. This includes submitting comprehensive data packages that include preclinical and clinical trial results, manufacturing information, and safety data. Clearside also engages with regulatory agencies early in the development process to obtain guidance on clinical trial design and regulatory strategy. The company's experience with XIPERE's approval provides a valuable framework for navigating future regulatory submissions.
What are the key factors to evaluate for CLSD?
Clearside Biomedical, Inc. (CLSD) holds an AI score of 51/100 (moderate). Analysts target $60.00 (+14534%). Not financial advice.
How frequently does CLSD data refresh on this page?
CLSD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CLSD's recent stock price performance?
Clearside Biomedical, Inc. (CLSD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative suprachoroidal space (SCS) drug delivery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- Analyst opinions are based on limited coverage and may not be representative of all viewpoints.
- Clinical trial outcomes are inherently uncertain and subject to change.